Sodium alginate-based drug delivery for diabetes management: A review

Diabetes mellitus (DM) is among the biggest global health problems of the 21st century, which is characterised by insufficient insulin secretion and results in the augmentation of blood sugar levels. The current foundation of hyperglycemia therapy is oral antihyperglycemic medications like biguanides, sulphonylureas, alpha-glucosidase inhibitors, peroxisome proliferator-activated receptor gamma (PPAR-gamma) agonists, sodium-glucose co-transporter 2 (SGLT-2) inhibitors, dipeptidyl peptidase-4 (DPP-4) inhibitors and others. Many naturally occurring substances have shown promise in treating hyperglycemia. Inadequate prologitivity of action, restricted bioavailability, site specificity, and dose-related side effects are some problems with currently available anti-diabetic medications. Sodium alginate has shown promise as a drug delivery mechanism, potentially solving issues with current therapies for several substances. This review summarizes the research on the efficacy of drug delivery systems based on alginate for transporting oral hypoglycemic medicines, phytochemicals, and insulin for treating hyperglycemia.

Automated summary

Diabetes mellitus is a major global health problem characterized by insufficient insulin secretion and increased blood sugar levels. Current treatment methods include oral antihyperglycemic medications, but they have limitations such as limited effectiveness and side effects. Sodium alginate, a drug delivery mechanism, has potential in solving these issues. This review summarizes the research on using alginate-based drug delivery systems for transporting oral hypoglycemic medicines, phytochemicals, and insulin to treat hyperglycemia.